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2Abstract
Soft-tissue mineralization is a tightly regulated process relying on the activity of systemic 
and tissue-specific inhibitors and promotors of calcium precipitation. Many of these, such as 
matrix gla protein (MGP) and osteocalcin (OC), need to undergo carboxylation to become active. 
This posttranslational  modification is catalyzed by the gammaglutamyl carboxylase GGCX and 
requires vitamin K (VK) as an essential co-factor. Recently, we described a novel phenotype 
characterized by aberrant mineralization of the elastic fibers resulting from mutations in GGCX. 
Because of the resemblance with pseudoxanthoma elasticum (PXE), a prototype disorder of 
elastic fiber mineralization, it was coined the PXE-like syndrome. As mutations in GGCX 
negatively affect protein carboxylation, it is likely that inactive inhibitors of calcification contribute 
to ectopic mineralization in PXE-like syndrome. Because of the remarkable similarities with PXE, 
we performed a comparative study of various forms of VK-dependent proteins in serum, plasma 
(using ELISA) and dermal  tissues (using immunohistochemistry) of PXE-like and PXE patients 
using innovative, conformation-specific  antibodies. Furthermore, we measured VK serum 
concentrations (using HPLC) in PXE-like and PXE samples to evaluate the VK status. 
In PXE-like patients we noted an accumulation of uncarboxylated Gla-proteins, MGP and 
OC, in plasma, serum and in the dermis. Serum levels of VK were normal in these patients. In 
PXE patients, we found similar, although not identical  results for the Gla-proteins in the circulation 
and dermal  tissue. However, the VK serum concentration in PXE patients was significantly 
decreased compared to controls. 
Our findings allow us to conclude that ectopic  mineralization in the PXE-like syndrome 
and in PXE results from a deficient protein carboxylation of VK-dependent inhibitors of 
calcification. While in PXE-like patients this is due to mutations in the GGCX gene, a deficiency of 
the carboxylation co-factor VK is at the basis of the decreased activity of calcification inhibitors in 
PXE. 
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3Abbreviations 
BMP2 (bone morphogenetic protein 2), ELISA (enzyme-linked sorbent immuno-assay), gas-6 
(growth-arrest specific  protein 6), HPLC (high-performance liquid chromatography), IHC 
(immunohistochemistry), PXE (pseudoxanthoma elasticum), MGP (matrix gla protein), cMGP 
(carboxylated MGP), ucMGP (uncarboxylated MGP), pMGP (phosphorylated MGP), dpMGP 
(dephosphorylated MGP), OC (osteocalcin), cOC (carboxylated OC), ucOC (uncarboxylated OC), 
ON (osteonectin), OPN (osteopontin), RT (room temperature), VK (vitamin K)
Keywords: elastic  fibers, elastorrhexis, fetuin-A, Gla-proteins, matrix Gla protein, mineralization, 
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4 Soft-tissue calcification is a highly regulated process relying on both systemic  and tissue-
specific balances of inhibitors and promotors of calcium precipitation. Fetuin-A (α2-Schmid-
Herremans glycoprotein), a member of the cystatin family of protease inhibitors produced 
predominantly by the liver, is considered an important circulating inhibitory factor of soft tissue 
mineralization (1). Among local  regulators, matrix gla protein (MGP), osteopontin (OPN) and bone 
morphogenetic protein-2 (BMP-2) are diversily associated with tissue mineralization in vivo 
(2,3,4).  Proteins primarily involved in the regulation of bone mineralization, such as osteocalcin 
(OC) or osteonectin (ON), have also been linked to local  extraosseous regulation of calcium 
homeostasis (5). 
Among all, MGP is considered the key physiological inhibitor of soft tissue calcification, 
acting as a direct inhibitor of calcium crystal formation as MGP deficient mice suffer from 
spontaneous and ultimately fatal calcification of arteries and cartilage (6). Together with OC and 
the clotting factors II, VII, IX and X, MGP needs to undergo carboxylation of glutamate (Glu) into 
gamma-carboxyglutamate (Gla) residues to become active. Carboxylation catalyzed by the 
endoplasmic gammaglutamyl carboxylase (GGCX) to form Gla-residues in all these proteins 
requires vitamin K (VK) as a co-factor, hence the terms “VK-dependent" or "Gla"-proteins (7). 
MGP, unique among the Gla-proteins, also has the tandemly repeated Ser-X-Glu sequence at the 
N-terminus end, which is a recognition motif for serine phosphorylation. Phosphorylation is 
thought to be carried out by the Golgi  casein kinase (8,9). It has been previously suggested that - 
next to being carboxylated - MGP must be fully phosphorylated at each target serine residue to 
have its optimal inhibitory activity on soft tissue calcification (9). 
Besides the gamma-carboxylase, the metabolic VK-cycle also involves the reductase 
enzyme VKORC1. Mutations in the GGCX or VKORC1 genes are associated with a hereditary 
deficiency of the VK-dependent clotting factors as well  as a clinically relevant dosing dependency 
of anti-coagulants [(10,11). Besides these enzymatic  defects, a deficiency of VK has been 
described in association with coagulation, bone (osteoporosis, osteoarthritis) and vascular 
(arteriosclerosis) disorders resulting from insufficient carboxylation of Gla-proteins (12,13).
We recently described an additional phenotype resulting from sequence changes in the 
GGCX gene (chrom. 2p12; OMIM#137167). This novel autosomal recessive disorder was 
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5characterized by a generalized deficiency of the VK-dependent clotting factors as well as 
mineralization and fragmentation of elastic fibers leading to thickened, inelastic skin and limited 
retinopathy (14). This disease was coined the “PXE-like syndrome” (OMIM#610842) because of 
its remarkable clinical and histological  resemblance with pseudoxanthoma elasticum (PXE, 
OMIM#264800), a prototype disorder of elastic  fiber mineralization (15,16). PXE is caused by 
mutations in the ABCC6 gene (chrom. 16p13.1; OMIM#603234), coding for an ATP-dependent 
transmembrane transporter, which is most abundant in liver and kidney (17,18). Neither the 
substrate of ABCC6 nor its relation to ectopic mineralization or elastic fiber changes observed in 
PXE is presently known.
As GGCX mutations in the PXE-like syndrome negatively affect protein carboxylation, we 
and others hypothesized that elastic fiber mineralization results from deficient VK-dependent 
inhibitors of calcification, such as MGP and OC. Recently reported findings already point towards 
a role of MGP in classic  PXE, but neither the involvement of other Gla-proteins nor the 
mechanism for such involvement have been studied yet (19-22). Because of the remarkable 
phenotypical similarities of the PXE-like syndrome and PXE and the absence in PXE of GGCX or 
VKORC1  mutations – which both have the potential of disrupting the VK-cycle -, we wondered 
whether the VK-cycle could also be disturbed by another mechanism in PXE. More precisely, we 
hypothesized that disturbances in Gla-proteins in PXE patients could be linked to VK, the cofactor 
in the VK-cycle and an essential mediator of Gla-protein carboxylation.  
We aimed to evaluate these hypotheses by studying the various forms of Gla-proteins in serum 
and tissues of PXE-like syndrome and PXE patients by using innovative antibodies. The latter 
were designed to specifically measure and differentiate between carboxylated and 
uncarboxylated forms of the proteins in immunohistochemistry (IHC) as well  as in ELISA assays. 
Furthermore, we evaluated the VK status in PXE-like and PXE patients by HPLC measurement of 
VK serum concentrations.
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6Materials and methods
Patients 
PXE and PXE-like patients were clinically evaluated in the Department of Genetics of the 
Ghent University Hospital (Belgium), the Department of Dermatology of the Orleans Hospital 
(France), and the Department of Biomedical  Sciences, University of Modena and Reggio Emilia 
(Italy). The diagnosis of PXE or the PXE-like syndrome was confirmed via molecular analysis of 
the ABCC6 or GGCX gene respectively, the methodology and results of which have been 
previously reported (14-16). The demographic  characteristics of the patient cohorts used in this 
study are summarized in table 1. Informed consent was obtained from all patients and the 
Declaration of Helsinki protocols were followed. This study was approved by the Ethical 
Committee of the Ghent University Hospital.
Biochemical measurements
 Serum was prepared by incubating the samples for 20 minutes at RT and subsequent 
centrifugation (10 min, 3000xg); plasma was prepared in citrate tubes. All  samples were frozen 
within 2h after blood collection. 
 Mineralization inhibitor levels were quantified in serum and citrate plasma of 4 PXE-like 
and 16 PXE patients using the ELISA technique. For measurement of the total fraction of 
uncarboxylated MGP (ucMGP), a competitive ELISA assay was applied (23,24). 
 Two additional sandwich ELISAs were developed at VitaK BV, Maastricht, The 
Netherlands, to determine the respective plasma levels of desphospho carboxylated (dp-cMGP) 
or desphospho uncarboxylated (dp-ucMGP) MGP. In brief, monoclonal anti-dpMGP was coated to 
the microtiter plate. After blocking, either patient plasma or standards were incubated. The 
standard peptide was synthetic MGP, based on the non-phosphorylated 3–15aa sequence and 
either the non-carboxylated 35–54aa sequence or carboxylated 35-54aa sequence, linked with a 
hydrophilic  spacer (Pepscan, Lelystad, the Netherlands). After incubation and washing, the 
standard or sample was detected using a biotinylated monoclonal ucMGP antibody or biotinylated 
cMGP antibody. 
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7 For measurements of total  osteocalcin, uncarboxylated (ucOC) and carboxylated (cOC) 
osteocalcin we used conformation-specific  sandwich ELISAs (Takara Shuzo Co Ltd., Shiga, 
Japan). Results of the MGP and OC measurements were compared with serum levels obtained in 
a for sex and age comparablecontrol population of 55 individuals (Table 1). 
 Vitamin K1 serum concentrations were assessed in 4 PXE-like and in 30 PXE patients 
using an HPLC technique with post-column reduction and fluorescence detection, as previously 
described (25, 26). None of the patients were taking VK supplements or coumarins at the time of 
measurement. Serum VK1 levels in patients were compared with those of a for sex and age 
comparable reference population of 34 healthy men and women (Table 1). 
Immunohistochemistry
 IHC was performed on skin biopsy specimens from 3 female patients with the PXE-like 
syndrome reported in a previous study (14), and on skin samples from 9 patients (1 male and 8 
females) with a clinical, histological and molecular diagnosis of PXE. Normal age- and sex-
matched skin biopsy samples from 7 individuals and lesional skin from 3 patients with solar 
elastosis or elastofibroma were used as controls (Table 1).
Light microscopy was performed on tissues embedded in paraffin. Antibodies against cMGP, 
ucMGP, fetuin-A, ON, BMP-2, gas-6 and OC were provided by VitaK (Maastricht, the 
Netherlands) [Schurgers et al, 2005]. The mAb against OC and polyclonal  antibodies against 
gas6, fetuin, OPN, ON and BMP-2 stained total protein (27). After deparaffinization, sections were 
heated in 0.2% citric  acid at pH 6.0, washed with phosphate-buffered saline and incubated with 
the primary antibody. For the polyclonal antibodies, citric  acid treatment was not added. All 
antibodies were diluted in blocking reagent (Roche Diagnostics, Mannheim, Germany). Negative 
controls were performed by omitting the primary antibody. Biotinylated sheep anti-mouse IgG 
(monoclonal antibodies - Amersham Biosciences, Little Chalfont, UK), swine anti-Rabbit IgG 
(polyclonal  antibodies - Dako, Golstrup, Denmark) or anti-goat IgG (BMP-2 - Dako, Golstrup, 
Denmark) were used as a second antibody (1h at RT), followed by incubation with the avidin-
linked peroxidase complex (Dako, Golstrup, Denmark); staining was performed by the AEC 
revelation kit (brown stain; Dako). Sections were counterstained with haematoxylin and mounted 
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8with cover slips. All  labellings were performed and evaluated independently by OMV and LM to 
assess reproducibility. The intensity of the staining was qualified in each section as ‘absent’ (0), 
‘light’ (+), ‘moderate’ (++) or ‘heavy’ (+++). 
Electron microscopy was performed on  skin biopsies which were fixed in 2.5% glutaraldehyde in 
Tyrode’s saline pH 7.2 (16-20h at 4°C), post-fixed in 1% osmium tetroxide (Fluka AG Chem) in 
the same buffer for 2h at RT, dehydrated in ethanol  and propylene oxide and embedded in Spurr 
resin (Polysciences Inc., Warrington, PA). Some specimens were rescued from formalin fixed and 
paraffin embedded biopsies. Ultrathin sections were collected on nickel grids and processed for 
immunocytochemistry as already described (28). Unspecific epitopes were neutralized by 
incubating sections on 0.5% bovine serum albumin in buffer. Monoclonal antibodies towards 
uncarboxylated and carboxylated species of MGP were used in parallel  in all experiments where 
controls and patient samples had to be compared. Immunoreactions were revealed by secondary 
antibodies conjugated with 10 nm gold particles (E.Y. Laboratories, San Mateo, CA). Controls 
were performed by omitting the primary antibody or by incubating sections with non-immune sera 
instead of the primary antibody. Sections were then stained with uranyl acetate and lead citrate 
and observed by transmission electron microscopy (Jeol, EM1200, Tokyo, Japan). 
 The intensity of immunostaining was evaluated by counting the number of gold particles 
per unit area. More than 20 different and randomly selected areas were analyzed and mean 
values and standard deviations were calculated. Since the reactivity of the two antibodies is 
different, comparison was made only between samples processed in parallel with the same 
antibody.
Statistical analysis
 All data given are means of duplicate measurements. Normality distribution was checked 
by the Kolmogorov-Smirnov test. Differences between groups were compared using the non-
parametricMann-Whitney U test and were considered significant at p <0.05. Ratios of 
uncarboxylated over carboxylated OC and MGP were calculated by dividing the measured level 
of the uncarboxylated form by the measured value of the carboxylated form. For vitamin K 
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parametric Median test and considered significant at p<0.05.
Results
A. Biochemical measurements
 Serum and plasma concentrations of OC (Figure 1 & 2). The total  amount of OC was 
significantly higher in the circulation of PXE-like patients compared to controls, being 17 ng/ml 
and 9 ng/ml, respectively. Elevated levels of circulating ucOC were demonstrated (Fig 1a & 2a), 
whilst cOC levels were diminished (Fig 1c  & Fig 2b), resulting in significantly higher ucOC/cOC 
ratio compared to the reference population (Fig 1e & Fig 2c). In PXE, the total amount of OC was 
slightly lower than in control sera, being 7,5 ng/ml in patients and 9,0 ng/ml  in controls. No 
significant abnormalities were noted in levels of cOC or ucOC.  
 Serum and plasma concentrations of MGP (Figure 1 & 2). For MGP, both the 
sandwich and competitive ELISA assays were used. In PXE-like patients, an increase of the dp-
ucMGP isoform (Fig 1g & Fig 2d) with a very high uc/cMGP ratio compared to controls (Fig 1k & 
Fig 2f) was shown. Competitive ELISA measurement of total ucMGP revealed significantly 
decreased serum levels (Fig 1m & Fig 2g). In PXE patients, no alterations were observed of dp-
cMGP and dp-ucMGP, nor in their respective uc/c  ratios using sandwich ELISA compared to 
control  samples (Fig 1h,j,l & Fig 2d,e,f). The competitive assay for total  ucMGP however showed 
decreased serum levels, similar to PXE-like patients (Fig 1n & Fig 2g). 
 Serum concentration of vitamin K (Figure 1 & 2). The serum VK concentration in PXE-
like patients was normal compared to a control  population (0.58 ng/ml vs. 0.60 ng/ml in the 
reference population; p>0.1) (Fig 1o, Fig 2h). In PXE patients, the median serum VK 
concentration was significantly decreased (0.12 ng/ml; SD= 0.31; p< 0.05) (Fig 1p, Fig 2h). In 
some PXE patients (n=5), the VK concentration was below the detection limit. 
B. Pathology findings
Light microscopy (Figure 3 & 4, Table 2). In PXE-like patients, labelling for cMGP and 
ucMGP was strongly positive in the mid-dermal elastorrhexis area (Figure 3e & f) and absent in 
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elastorrhexis-free areas and in control samples (Figure 3a & b). In PXE patients, similar findings 
were observed for cMGP (Figure 3d). Although ucMGP stained somewhat less intense in the 
elastorrhectic fibers compared to those in PXE-like syndrome, it was still significantly more 
prominent compared to controls (Figure 3c).
Labelling for OC was weakly to moderately positive in the epidermis and elastorrhexis 
zone of PXE-like and PXE patients compared to controls (Figure 4c). OC was the only protein 
that also stained weakly positive in fibroblasts, compared to moderate staining in controls. 
Fetuin-A stained heavily in the area of elastorrhexis as well  as subepidermally - in the 
upper papillary dermis (Figure 4d). In PXE, significant staining was also seen in the elastorrhexis 
zone while the sub-epidermal labelling was less prominent compared to PXE-like tissues. 
Both OPN and BMP2 stained strongly in the elastorrhexis zone in PXE and PXE-like, 
compared to very weak or no staining in controls (data not shown).
Electron microscopy (Figure 5, Table 3 & 4). In the dermis of PXE-like patients and 
controls, fibroblasts were negative for ucMGP. By contrast, fibroblasts were slightly positive for 
cMGP in controls and negative in PXE-like patients (Table 3). In the extracellular space, elastic 
fibers were the only matrix constituent positive for both forms of MGP in PXE-like patients and in 
controls (Table 3). The evaluation of the number of gold particles per 1 µm2 on the apparently 
normal elastic fibers revealed that ucMGP was more abundant within the fibers of PXE-like 
patients compared to controls, the number of gold particles being 46.7±26.5 / µm2 in patients and 
27±8.2 / µm2 in controls (p<0.001) (Figure 5e & a, Table 4). The antibody recognizing cMGP was 
more abundant within the elastic fibers of controls than in the apparently normal ones of PXE-like 
patients, being 5.7±3.1/µm2 in controls and 2.1± 1.8/µm2 in patients (p<0.001; Table 4). The 
antibody recognizing ucMGP reacted with epitopes abundantly present in bulky calcium 
precipitates (data not shown) and in the core of calcified elastic fibers (Figure 5e). By contrast, 
the antibody recognizing cMGP primarily localized at the border of the finely mineralized areas 
within elastic fibers separating calcified from still normal elastin (Figure 5b & f).
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In the dermis of PXE patients, fibroblasts were negative for ucMGP and barely positive 
for cMGP. In general, PXE fibroblasts were less positive for cMGP compared to controls (Table 3) 
(20). In the extracellular space, the distribution of positive immunostaining for cMGP and ucMGP 
gave results almost identical to those in patients with the PXE-like syndrome (Figure 5c & d). 
Irrespective of the calcification degree, elastic  fibers were the only extracellular matrix component 
positive for both antibodies. The immunoreaction for ucMGP, the inactive form of MGP, was 
slightly more intense on PXE elastic  fibers compared to controls (Table 3 & 4). Moreover, as 
already reported (20), it was confirmed that ucMGP antibodies were associated with either bulky 
and finely dispersed mineral  precipitates inside elastic  fibers (Figure 5c), whereas cMGP 
antibodies nicely and precisely localised at the border of the mineralised areas of calcified elastic 
fibers  (Figure 5d).     
C. Control experiments
In both PXE-like and PXE patients, Gla-proteins which are not involved in calcium 
homeostasis, such as gas-6, did not stain the elastorrhexic fibers (data not shown). MGP, OC and 
fetuin-A labellings did not yield a positive stain in solar elastosis or elastofibroma samples used 
as controls of skin conditions with dystrophic but non-mineralized elastic fibers (data not shown)
Discussion 
 The present study confirms that inactive VK-dependent Gla-proteins are present both in 
the circulation and locally in dermal tissue of PXE and PXE-like patients. While in PXE-like 
patients this is likely due to the GGCX mutations, PXE patients tend to present decreased serum 
levels of VK, the essential co-factor of the VK-cycle, necessary for gamma-carboxylase activity.
A. VK-dependent proteins in PXE-like patients
In this study we first evaluated the hypothesis that low levels of carboxylated species of 
MGP and OC results in elastic fiber mineralization in PXE-like patients affected by GGCX 
mutations. We noted a significant accumulation of uncarboxylated MGP in dermal  elastorrhexis. 
Quantitative analysis at the ultrastructural level  confirmed the abundance of uncarboxylated MGP 
and unusually low amounts of carboxylated protein compared to controls. Sandwich ELISA 
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assays in serum and plasma of PXE-like patients revealed decreased levels of carboxylated 
forms of MGP and OC while the levels of immature forms, respectively uncarboxylated 
unphosphorylated MGP and the total fraction of uncarboxylated OC, were dramatically increased. 
As a result, carboxylated/uncarboxylated ratios of both MGP and OC were decreased. Indeed, all 
these findings are the direct consequences of GGCX deficiency and are factors likely to favour 
calcium precipitation in tissues such as the skin. 
Two findings need further interpretation. First, competitive ELISA experiments, specifically 
measuring total uncarboxylated MGP (dp-ucMGP and p-ucMGP), showed unexpectedly 
decreased serum levels. This may be explained by the high affinity of the phosphorylated ucMGP 
fraction (the most abundant form) for calcium in contrast to the unphosphorylated ucMGP. Hence 
the former may accumulate in the calcified tissues resulting in low serum levels. Secondly, 
labelling for cMGP and OC was clearly positive in all PXE-like skin samples. Interestingly, cMGP 
and ucMGP localised in different areas of mineralised elastic  fibers in patients. Similarly to what 
observed in the dermis of PXE patients (20), cMGP was at the border of mineralization, whereas 
ucMGP was heavily associated with mineral precipitates (Figure 5). The presence of carboxylated 
species in lesional skin and plasma indicates that the VK-metabolism was not completely 
abolished. Yet, the amount of cMGP and OC accumulating at sites of calcium precipitation appear 
to be far below the critical  threshold necessary to limit the calcification process. In a single 
pedigree displaying PXE-like features, Li et al. recently reported that dermal elastorrhexis only 
weakly expressed carboxylated MGP (22). In the latter paper both mutations detected in the 
GGCX gene were associated with different reduction in gamma-carboxylase activity. We did not 
measure the gamma-carboxylase activity in our own patients but it seems likely that they keep a 
significant enzyme activity, since about 30% of carboxylated MGP and OC was still  present in the 
circulation, although not sufficient to avoid connective tissue calcification. 
The intensity of OC labelling in middermal elastorrhexis suggests an additional local role 
for this Gla-protein, albeit more limited. Even though the lack of conformation-specific antibodies 
does not allow us to demonstrate that most OC in lesional skin is uncarboxylated, our finding of 
increased serum and plasma levels of uncarboxylated OC in PXE-like patients corroborates with 
this possibility.
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Besides the local calcification inhibitors MGP and OC, we observed strong staining of the 
potent systemic  inhibitor of calcification fetuin-A in the dermis of PXE-like patients. This serum 
protein carries calcium phosphate and has been shown to play a major role in preventing 
pathological calcification (29-31). The extent of the protective mechanism by fetuin-A however 
appears to be less than that exerted by MGP, as fetuin-A deficient mice only develop minor 
calcified lesions compared to the extensive calcifications in Mgp -/- mice (30). However, fetuin-A 
is closely related to the extracellular transport of MGP. Price et al. have shown that cMGP, but not 
ucMGP, is carried by fetuin-A in plasma (8). This suggests that VK-dependent post-translational 
carboxylation of MGP is essential for fetuin-A binding and transport, and therefore could influence 
calcium deposition in the PXE-like syndrome resulting in a two hit mechanism for the promotion of 
calcification via MGP. 
Measurement of VK in serum of PXE-like patients revealed normal concentrations. This 
confirms the hypothesis that in PXE-like syndrome ectopic  mineralization is primarily the result of 
the GGCX mutations causing inactive Gla-proteins. 
B. VK-dependent proteins in PXE patients
The identification of the PXE-like syndrome opened an interesting avenue of comparative 
research in PXE, because of the resemblance of both phenotypes. We therefore evaluated the 
involvement of MGP, OC and fetuin-A in PXE skin samples and observed similar IHC results as in 
PXE-like tissues. Biochemical measurements also revealed a decrease of serum and plasma 
total  ucMGP, but - in contrast to PXE-like patients - normal concentrations of dp-ucMGP were 
found. 
Contrary to PXE-like patients, none of the PXE patients had mutations or functionally 
relevant polymorphisms in the GGCX gene, which could explain a possible dysregulation of the 
VK-cycle. We therefore also evaluated serum concentrations of VK, the essential  co-factor of this 
metabolic  cycle. We observed a poor vitamin K1 status in PXE patients with median serum 
concentrations much lower than these measured in the reference population (0.12 ng/ml  vs 0.60 
ng/ml, SD= 0.31, p<0.05) or in other disorders associated with Gla-protein-related abnormal 
mineralization such as Crohn’s disease or osteoarthritis (13,32). In 5 PXE patients, the VK 
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concentration was below the detection limit, as observed in disorders with malabsorption of fat-
soluble vitamins such as cystic fibrosis (33). 
These low VK serum concentrations would suggest that gamma-carboxylation of OC is 
also negatively affected in PXE. Surprisingly, we did not detect abnormal OC levels in PXE serum 
samples, despite the IHC resemblance of labellings for OC with PXE-like syndrome, in which 
highly disturbed OC serum levels were noted. Osteoblasts, the cell type most expressing OC, 
have however a high level of low-density lipoprotein receptor-related protein 1 (LRP1) on their 
surface. LRP1 allows efficient uptake of the apoprotein E-containing chylomicron remnants that 
carry the bulk of the diet-derived VK. Therefore, it is plausible to assume osteoblasts to be more 
efficient in acquiring their share of the inadequate amounts of circulating VK in PXE patients that 
e.g. vascular smooth muscle cells in arteries or fibroblasts in skin (34). 
The observation of such poor VK status in PXE patients supports the recently suggested 
hypothesis of VK as a candidate substrate of the ABCC6 transporter, which could provide a link 
between mutations in the ABCC6 gene, deficient protein carboxylation and resulting 
mineralization of elastic fibers (35). 
The increased expression of OPN, a mineral-binding phosphoprotein abundant in several 
mineralized tissues, in both PXE and PXE-like can be considered a rescue response to MGP 
dysfunction (36). OPN upregulation in mineralized aorta of Mgp -/- mice has previously been 
proposed to act as a secondary, inducible, calcification inhibitor which limits further mineralization 
(3). In Mgp  -/- mice, OPN initiates removal of the mineral by macrophages (37). Of note, 
macrophages have also been found to be abundant near calcified areas in PXE dermis (38). 
MGP has been shown to negatively regulate BMP2, a known osteoinductive protein (39). The 
observed upregulation of BMP2 may likewise be due to MGP dysfunction.
By immunoelectron microscopy it has been confirmed that ucMGP is specifically 
associated with calcification in both disorders and that the scarce cMGP present in the dermis of 
patients is precisely localised at the boundary separating calcified from normal elastin so 
appearing to inhibit/limit mineralization. Previous IHC reports on ectopic mineralization, showing 
involvement of various glycoproteins such as vitronectin or bone sialoprotein were hampered by 
the low specificity of these findings (40). In the present study, samples of disorders with 
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dystrophic  elastic fibers but no mineralization, such as elastosis or elastofibroma, did not yield 
any MGP, OC or fetuin labellings, suggesting that our observations are highly specific for PXE 
and the PXE-like syndrome. Similarly, labelling for Gla-proteins not involved in calcium 
homeostasis, such as gas-6, were negative.
 
From our findings, we can conclude that ectopic  mineralization in the PXE-like syndrome 
and in PXE results from a deficient carboxylation of VK-dependent inhibitors of calcification. In the 
PXE-like syndrome, this deficiency results directly from mutations in the gamma-carboxylase 
gene. In PXE, deficiency of the carboxylation co-factor VK is at the basis of the decreased activity 
of calcification inhibitors. In both disorders MGP has a critical place. Whether VK is indeed the 
substrate of ABCC6 needs further study. However, our observations are promising towards 
therapeutic interventions in PXE, a disorder with no treatment to date. It has been shown in other 
disorders with poor VK status that exogenous VK supplementation enhances the level of γ-
glutamyl-carboxylation, increasing the levels of carboxylated Gla-proteins, and as such (partially) 
inhibiting calcium precipitation. In animal models with deficient VK-dependent calcification 
inhibitors, ectopic calcification could be partially rescued with high doses of VK (25). As it is 
possible that other inhibitory pathways of calcification, such as the Ank-pathway in the Abcc6-/- 
mice (41), or other genes are also involved in clinical manifestations of human PXE and PXE-like 
syndrome, the extent of the VK supplementation effect remains to be determined in a clinical 
setting.
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Titles and legends to figures
Figure 1 A. Graphical representation of sandwich ELISA and competitive ELISA (m&n) 
measurement results in PXE-like and PXE patients, compared to controls. For PXE-like, 
significant differences are observed in all measurements except dp-cMGP and vitamin K serum 
concentrations. For PXE, significant differences can be seen  ucMGP and vitamin K can be seen.
uc: uncarboxylated; c: carboxylated; dp: dephosphorylated; OC: osteocalcin; MGP: matrix gla 
protein; VK: vitamin K; * p< 0.05. B. Quantitative data on the sandwich and competitive ELISA 
measurements in PXE and PXE-like patients. Values are means, except †: median values. Co: 
controls; NS: not significant.
Figure 2 Scatter plot representation of sandwich ELISA and competitive ELISA (g) measurement 
results in PXE-like and PXE patients, compared to controls. Red lines represent mean values. 
For PXE-like, significant differences are observed in all measurements except dp-cMGP and 
vitamin K serum concentrations. For PXE, significant differences can be seen  ucMGP and 
vitamin K can be seen. uc: uncarboxylated; c: carboxylated; dp: dephosphorylated; OC: 
osteocalcin; MGP: matrix gla protein
Figure 3 IHC staining results for carboxylated MGP (cMGP) and uncarboxylated MGP (ucMGP), 
respectively in controls (a-b), PXE patients (c-d) and PXE-like patients (e-f). Significant staining of 
cMGP and ucMGP in the elastorrhexis areas is seen in PXE and PXE-like patients.
Figure 4 IHC staining for osteocalcin and fetuin-A in controls (a-b) and PXE-like patients (c-d). 
Weakly to moderately positive staining for OC and heavy staining for fetuin-A is seen in PXE-like 
patients. In PXE, similar labeling was observed as in PXE-like patients. Middermal labelling is 
marked with asterisk; subepidermal labelling is arrowed. 
Vanakker et al.
22
Figure 5 Transmission electron microscopy of elastic fibers in the skin of  control subjects (a-b), 
PXE (c-d) and PXE-like patients (e-f). Gold particles represent epitopes positive to anti-ucMGP 
(a, c, e) and  -cMGP (b, d, f) antibodies. In PXE-like patients, ucMGP was more abundant 
compared to controls while the contrary was seen for cMGP. In PXE patients, similar results were 
obtained, although less pronounced, for staining of elastic fibers. In both diseases, ucMGP 
antibodies were located in the core of the elastic fibers, while cMGP antibodies localised at the 
border of the mineralised areas. Bars: 1µm and 0.5µm (inserts).
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Table 1 Demographic characteristics of the patient and control cohorts
Experiment Patient cohort F:M ratio Mean age 
(in yrs.)
Mean duration of 
disease (yrs)
ELISA calcification inhibitors 16 PXE 13:3 56 (14; 28-75) 15 (11; 3-40)
4 PXE-like 4:0 50 (13; 33-71) 15 (10; 6-32)
55 Controls 29:26 58 (10; 30-75) -
HPLC vitamin K 30 PXE 20:10 49 (15; 14-79) 16 (14; 2-41)
4 PXE-like 4:0 50 (13; 33-71) 15 (10; 6-32)
34 Controls 21:13 45 (14; 18-75) -
Immunohistochemistry 9 PXE 5:4 52 (17; 31-79) 14 (10; 5-40)
3 PXE-like 3:0 57 (9; 50-71) 15 (12; 6-32)
7 Controls 5:2 55 (10; 33-76) -
F= female; M= male; Mean age (standard deviation; range); Mean duration of disease (standard 
deviation; range); yrs= years
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Table 2 Semiquantitative summary of immunohistochemical findings.
Papillary
dermis
Normal
elastic fibers
Elastorrhexis Fibroblasts
PXE
ABCC6
(n=9)
cMGP
ucMGP
Fetuin-A
Osteocalcin
0
0
0
0
0
0
0
0
+++
+ (punct.)
+++
+ (punct.)
0
0
0
+
PXE-like
GGCX
(n=3)
cMGP
ucMGP
Fetuin-A
Osteocalcin
0
0
+++
0
0
0
0
0
+++
++ (>ABCC6)
+++
+ (punct.)
0
0
0
+
Controls
(normal skin)
(n=7)
cMGP
ucMGP
Fetuin-A
Osteocalcin
0
0
0
0
0
0
0
0
NA
0
0
0
++
Controls
(dystrophic 
elastic fibers)
(n=3)
cMGP
ucMGP
Fetuin-A
Osteocalcin
0
0
0
0
0
0
0
0
Dystrophic 
fibers
0
(internal positive 
controls + ; eg. 
endothelial cells)
0
0
0
+
cMGP= carboxylated matrix gla protein; ucMGP= uncarboxylated matrix gla protein; 
n= number; NA= not available; punct= punctuated
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Table 3 Relative positivity of the dermal components towards the antibodies recognizing cMGP 
and ucMGP assayed by immunoelectron microscopy. Only reactions performed with the same 
antibody can be compared. 
Fibroblasts Normal elastic fibers Calcified elastin
cMGP ucMGP cMGP ucMGP cMGP ucMGP
Controls + - +++ +++ // //
PXE-like - - ++ +++++ ++ ++++++
PXE ± - + ++++ ++ ++++++
cMGP= carboxylated matrix gla protein; ucMGP= uncarboxylated matrix gla protein 
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Table 4 Number of gold particles per µm2 counted on the elastic fibers of control dermis and on 
the apparently normal elastic fibers of the dermis of patients. 
Controls PXE PXE-like PXE 
vs Co
PXE-like 
vs Co
PXE-like 
vs PXE
cMGP 5.7±3.1 1.4±1.3 2.1±1.8 p<0.001 p<0.001 p<0.1
ucMGP 27.0±8.2 30.7±36.1 46.7± 26.5 p<0.7 p<0.001 p<0.02
cMGP= carboxylated matrix gla protein; ucMGP= uncarboxylated matrix gla protein; Co= controls
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